duchenne muscular dystrophy sarepta - Search News

Order byBest matchMost fresh

News

Sarepta reports 2nd patient death

· 20h · on MSN

Second patient death reported with gene therapy for muscular dystrophy

Shares of Sarepta Therapeutics have plunged again after the drugmaker reported a second death in connection with its gene therapy for muscular dystrophy.

Continue reading

· 1d · on MSN

2nd death reported in Sarepta gene therapy trial for Duchenne muscular dystrophy

Sarepta reports second patient death after treatment with Duchenne gene therapy

After second Sarepta death, Duchenne muscular dystrophy community is racked by recrimination and worry

Another gene therapy death of a Duchenne patient has some parents and doctors criticizing the FDA's actions, even as other ...

Managed Healthcare Executive1d

Sarepta Stops Shipments of Elevidys For Non-Ambulatory DMD Patients

A second patient with Duchenne muscular dystrophy has died from acute liver failure after receiving the gene therapy Elevidys ...

1d

Sarepta Therapeutics Stock Plummets Over 40% On Second Fatal Case Linked To Its Gene Therapy

Sarepta suspends Elevidys use in non-ambulatory Duchenne patients after two liver failure deaths, triggering FDA review and ...

2d

Sarepta Provides Safety Update for ELEVIDYS and Initiates Steps to Strengthen Safety in Non-Ambulatory Individuals with Duchenne

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today provided a safety ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results